论文部分内容阅读
目的:探讨甲胎蛋白、癌胚抗原125、β2-微球蛋白联合检测在良恶性腹腔积液鉴别诊断中的应用价值。方法:回顾性分析恶性腹腔积液患者51例,良性腹腔积液患者36例的腹腔积中液甲胎蛋白、癌胚抗原125、β2微球蛋白检测结果。结果:恶性腹腔积液患者腹腔积液中甲胎蛋白、癌胚抗原125、β2微球蛋白水平均高于良性腹腔积液患者(P<0.05);恶性腹腔积液患者腹腔积液中甲胎蛋白、癌胚抗原125、β2-微球蛋白单项检测阳性率分别为74.51%,64.71%,60.78%,特异性分别为83.33%、86.11%、80.56%;3项联合检测阳性率与特异性分别为86.27%,88.89%,均高于单项检测(P<0.05)。结论:腹腔积液甲胎蛋白、癌胚抗原125、β2微球蛋白联合检测对鉴别良、恶性腹腔积液有较高临床价值。
Objective: To investigate the value of combined detection of α-fetoprotein, carcinoembryonic antigen 125 and β2-microglobulin in the differential diagnosis of benign and malignant ascites. Methods: The clinical data of 51 cases of malignant ascites and 36 cases of benign ascites were analyzed retrospectively. Results: The levels of α-fetoprotein, carcinoembryonic antigen 125 and β2 microglobulin in patients with malignant ascites were significantly higher than those in patients with benign ascites (P <0.05), and those in patients with malignant ascites The positive rates of single detection of protein, carcinoembryonic antigen 125 and β2-microglobulin were 74.51%, 64.71% and 60.78%, respectively, with the specificity of 83.33%, 86.11% and 80.56% 86.27% and 88.89% respectively, all higher than single test (P <0.05). Conclusion: The combined detection of a-fetoprotein, carcinoembryonic antigen 125 and β2 microglobulin has a high clinical value in differentiating benign and malignant ascites.